CBP9106

CBS9106 (SL-801, Felezonexor) is a novel small molecule reversible inhibitor of Exportin-1 (XPO1 or CRM1), clinically validated target, to be administered orally.

Stemline Therapeutics, Inc., our global partner, is carrying on Phase 1 clinical trial in solid tumor.

For more info on CBS9106/SL-801 please visit Stemline website.